INT11622

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1992
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 26
Total Number 29
Disease Relevance 10.56
Pain Relevance 5.52

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
blood 1
hair 1
neurons 1
uterine 1
endometrium 1
Coc (Mus musculus)
Pain Link Frequency Relevance Heat
cocaine 98 100.00 Very High Very High Very High
Morphine 14 99.80 Very High Very High Very High
tolerance 32 99.40 Very High Very High Very High
ketamine 119 98.92 Very High Very High Very High
withdrawal 314 98.70 Very High Very High Very High
opiate 6 95.80 Very High Very High Very High
cannabis 16 95.08 Very High Very High Very High
drug abuse 58 92.84 High High
Cannabinoid 3 92.36 High High
Bioavailability 10 85.88 High High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 47 99.38 Very High Very High Very High
Hirsutism 39 98.64 Very High Very High Very High
Death 6 97.88 Very High Very High Very High
Reprotox - General 1 668 96.02 Very High Very High Very High
Hemorrhage 938 95.36 Very High Very High Very High
Emergencies 6 94.88 High High
Drug Induced Neurotoxicity 3 94.40 High High
Alopecia 24 93.76 High High
Drug Dependence 59 92.84 High High
Reprotox - General 2 201 89.12 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Compared with a COC containing 150 ?
Gene_expression (containing) of COC
1) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 0.07 Pain Relevance 0.04
In an open-label, one-center, controlled trial, 201 women were randomly assigned to NuvaRing (ITT = 78) or a triphasic COC containing norgestimate (0.18 mg during the first week; 0.215 mg during the second week; 0.25 mg during the third week) and 25 ?
Gene_expression (assigned) of COC
2) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 0.91 Pain Relevance 0.15
An open-label, single-center, cross-over study was carried out in which women were randomly assigned to either NuvaRing (ITT = 33) or a COC containing 100 ?
Gene_expression (containing) of COC
3) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 0.83 Pain Relevance 0
A prospective study during 1 year was carried out in 280 women who were randomized to either NuvaRing (n = 94), or a COC containing 100 ?
Gene_expression (containing) of COC
4) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 0.54 Pain Relevance 0
Healthy women with a permanent partner and an active sexual life were randomly assigned to NuvaRing (ITT = 26) or a COC containing 150 ?
Gene_expression (containing) of COC
5) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 0 Pain Relevance 0
However, significantly fewer breakthrough spotting episodes were observed in the NuvaRing group during cycles 1, 3, 4, 6, and 10 (p < 0.05), whereas significantly more early withdrawal bleedings were observed in the NuvaRing group compared with the COC group during cycles 1, 5, 8, and 12 (p < 0.05).
Gene_expression (group) of COC associated with withdrawal and reprotox - general 1
6) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 1.05 Pain Relevance 0.20
An open-label, single-center, cross-over study was carried out in which women were randomly assigned to either NuvaRing (ITT = 33) or a COC containing 100 ?
Gene_expression (assigned) of COC
7) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 0.84 Pain Relevance 0
g EE per day) compared with that for a COC containing 30 ?
Gene_expression (containing) of COC
8) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 0.38 Pain Relevance 0.08
Vaginal administration of contraceptive hormones with NuvaRing has the advantage of avoiding gastrointestinal absorption and hepatic first-pass metabolism, but does not produce elevated uterine concentrations of EE and ENG compared with a COC (Roumen and Dieben 2006).
Neg (not) Gene_expression (produce) of COC in uterine
9) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 0.08 Pain Relevance 0.04
In most randomized studies, discontinuation due to adverse events was higher in the NuvaRing groups than in the COC groups (NuvaRing: 11.3% (Oddsson et al 2005a), and 12.2% (Ahrendt et al 2006), versus COC: 8.7% (Oddsson et al 2005a), and 9.9% (Ahrendt et al 2006), respectively), due to the additional ring-related events.
Gene_expression (groups) of COC
10) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 0.66 Pain Relevance 0.18
g EE (100LNG/20EE) (n = 94), or a COC containing 60 ?
Gene_expression (containing) of COC
11) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 0.64 Pain Relevance 0
Pearl indices for the ITT population were 0.25 and 0.99 per 100 women-years for the NuvaRing and COC groups, respectively (Table 1).
Gene_expression (groups) of COC
12) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 0.28 Pain Relevance 0.10
In most randomized studies, discontinuation due to adverse events was higher in the NuvaRing groups than in the COC groups (NuvaRing: 11.3% (Oddsson et al 2005a), and 12.2% (Ahrendt et al 2006), versus COC: 8.7% (Oddsson et al 2005a), and 9.9% (Ahrendt et al 2006), respectively), due to the additional ring-related events.
Gene_expression (groups) of COC
13) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 0.66 Pain Relevance 0.18
Healthy women with a permanent partner and an active sexual life were randomly assigned to NuvaRing (ITT = 26) or a COC containing 150 ?
Gene_expression (assigned) of COC
14) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504064 Disease Relevance 0 Pain Relevance 0
In the KT-only groups, the same volumes of saline vehicle were injected instead of COC or MA.
Gene_expression (injected) of COC associated with ketamine and cocaine
15) Confidence 0.34 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1473192 Disease Relevance 0.08 Pain Relevance 0.80
In contrast to a decrease in HDL, HDL2, and HDL3 levels in the COC group, HDL2 increased in NuvaRing group.
Gene_expression (group) of COC associated with disorder of lipid metabolism
16) Confidence 0.34 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2990910 Disease Relevance 0.61 Pain Relevance 0.04
Measures of subjective effects were obtained repeatedly, heart rate, diastolic and systolic blood pressure were sampled every 2 min and blood levels of COC and MOR were obtained at three time points.
Gene_expression (levels) of COC in blood associated with morphine and cocaine
17) Confidence 0.30 Published 1992 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 1578376 Disease Relevance 0 Pain Relevance 1.40
g EE COC or the NuvaRing, uterine hormone levels were comparable in the upper and mid myometrium, and the cervical region.
Gene_expression (levels) of COC in upper
18) Confidence 0.29 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2990910 Disease Relevance 0 Pain Relevance 0.03
Conversely, endometrial concentrations of estrogen were higher in the COC group.
Gene_expression (group) of COC
19) Confidence 0.29 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2990910 Disease Relevance 0 Pain Relevance 0.03
Complete inhibition of ovulation as measured by follicle formulation and luteinizing hormone (LH) and progester-one levels was found during the typical 3 weeks of use and for 2 additional weeks.11 The endometrium was found to be thinned in all subjects and was comparable to the COC group.
Gene_expression (group) of COC in endometrium
20) Confidence 0.29 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2990910 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox